Asthma Sample Clauses

Asthma. The following services related to asthma are covered with $0 Out-of-Pocket Cost when linked to a primary diagnosis of asthma and performed by a Network Provider: • Office visits to a Primary Care Provider for routine management of asthma • Office visits to a Pulmonologist (lung specialist) for consultation and routine management of asthma • Office visits to an Allergist (allergy specialist) for consultation and routine management of asthma • Palliative care conversations (chronic condition treatment preferences) with Primary Care Provider, Pulmonologist, or Allergist • Immunotherapy for allergen sensitization to reduce impact and severity of allergic reactions • Inhaler adjuncts (e.g., spacer) as specified on the formulary and dispensed through our Home Delivery Program • Pulmonary function tests • Asthma education [allergens/triggers, asthma action plan and behavioral modification counseling] • Targeted laboratory tests for the routine management of asthma Please note, if you have complications from asthma and use an urgent care center, emergency department, or have a Hospital stay, services will be subject to standard Out-of-Pocket Costs as outlined in your Schedule of Benefits.
Sample 1Sample 2See All (6)
AutoNDA by SimpleDocs
Asthma. Asthma is a chronic, incurable disease which causes many symptoms that make breathing difficult [3]. Around 5% of the Medicare population in the Parkview area is affected by asthma, as well a portion of the population of adults and children. Asthma as a chief health concern was not mentioned in the community or provider surveys, but asthma in the Medicare population appeared as a primary concern in several of the seven counties according to HCI. While the population affected may be small, the disease burden is high due to expensive and potentially life-long costs associated with managing symptoms of asthma. There are several clinical intervention strategies recommended by healthcare professionals to reduce the frequency and severity of symptoms. Table 5: Asthma Xxxxx Xxxxxxxxxx Kosciusko LaGrange Noble Wabash Xxxxxxx Asthma 5.6% 6% 4.5% 3.6% 5.5% 4.8% 5.5%
Sample 1Sample 2Sample 3
Asthma. Implement targeted education and outreach activities to increase awareness of and disseminate resources on childhood asthma management, including management before, during and after a disaster. Grantee will: a. Develop and submit to DSHS on an approved template an education and outreach plan that identifies measurable objectives, activities for accomplishing objectives, timeframe for completion, and key partners. The plan should also include communication strategies and target audiences. The education and outreach plan must be submitted to DSHS within 30 days of contract execution. b. Develop and submit to DSHS an evaluation plan using a DSHS-approved template. The evaluation plan must be submitted to DSHS within 45 days of contract execution. c. Conduct outreach to at least five (5) communities/cities, specifically those severely impacted by Hurricane Xxxxxx to provide education and resources on childhood asthma management, including management before, during, and after a disaster by May 31, 2020. d. Conduct outreach to at least five (5) school districts to provide education and resources on childhood asthma management, including management before during and after a disaster by May 31, 2020. e. Submit monthly progress reports to the DSHS Contract Manager in compliance with the report submission schedule listed in the report template. The report will be provided by DSHS after contract execution. f. Submit a Final Progress Report Draft to DSHS using approved template. Report will include summary of all items/activities conducted to date; detailed description of progress toward achieving objectives and activities; plans for sustaining activities once funding has ended; and barriers/lessons learned. The Final Progress Report must be submitted to DSHS on June 14, 2020.
Sample 1
Asthma. Since phthalates are well-known endocrine disruptors, a large amount of research focuses on effects on the reproductive system, the thyroid and metabolism (Huang, Kuo, Guo, Liao, & Xxx, 2007; Lyche et al., 2009). We are interested in its influence on respiratory system. Asthma, characterized by recurrent bronchial hyperresponsiveness, is one of most common pulmonary diseases in the Xxxxxx Xxxxxx. Xx 0000-0000, asthma prevalence was 8.8% among adults. Overall asthma prevalence among adults increased from 2001-2002 (7.1%) to 2013-2014 (9.2%) (CDC). Common clinical symptoms of asthma include coughing, wheezing, shortness of breath and chest tightness. Symptoms are typically exacerbated at night and in the early morning or related to exercise or inspiration of cold air in winter. Airway inflammation, airflow obstruction, and irreversible airway remodeling are believed to be involved in asthma development. The respiratory system of a human contains two lungs, the trachea, the bronchi in the mediastinum, and the bronchial trees (bronchi branches). The trachea and its large proximal branches form a passageway for air exchange between the lung and the external environment (Gilroy, 2013). Asthma primarily targets at the bronchi and its subdivisions and conducting bronchioles. The pathogenesis of asthma can be classified into two categories. One is intrinsic asthma mainly caused by viral infection (e.g., rhinovirus, parainfluenza virus, respiratory syncytial virus), air pollutants, aspirin or other nonsteroidal medication use (Goljan, 2013). The other one is extrinsic asthma which involves a classical inflammation process. Mast cells, IgE antibodies, leukotrienes, chemokines and cytokines participate in the inflammation process and lead to histologic changes, such as thickening of the basement membranes, infiltration of inflammatory cells, hypertrophy of mucous glands, hypertrophy of smooth muscle cells and hyperplasia (Kumar, Abbas, & Aster, 2012). Narrowing of the bronchi causes expiratory wheezing in asthma, and the air trapping in distal bronchioles leads to the increased anteroposterior thoracic diameter, especially in long-term untreated asthma patients. Although the mechanisms have not yet been elucidated, there are several encouraging laboratory research findings pertaining to the cellular mechanisms through which phthalates may influence inflammation and allergic response. For example, the production of pro-inflammatory chemokines and cytokines in human mac...
Sample 1
Asthma 
Sample 1

Related to Asthma

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Screening After you sign and date the consent document, you will begin screening. The purpose of the screening is to find out if you meet all of the requirements to take part in the study. Procedures that will be completed during the study (including screening) are described below. If you do not meet the requirements, you will not be able to take part in the study. The study investigator or study staff will explain why. As part of screening, you must complete all of the items listed below: • Give your race, age, gender, and ethnicity • Give your medical history o You must review and confirm the information in your medical history questionnaire • Give your drug, alcohol, and tobacco use history • Give your past and current medication and treatment history. This includes any over-the-counter or prescription drugs, such as vitamins, dietary supplements, or herbal supplements, taken in the past 28 days • Height and weight will be measured • Physical exam will be done • Electrocardiogram (ECG) will be collected. An ECG measures the electrical activity of the heart • You may be tested for COVID-19 o Blood tests for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C o Blood tests to see how your blood clots ▪ Fibrinogen ▪ PT/INR/aPTT o Blood tests for amylase and lipase (enzymes that help with digestion, Part B only) o Blood tests for a lipid (fats) panel (Part B only) ▪ Total cholesterol ▪ Triglycerides ▪ HDL ▪ Direct HDL o Blood tests to check your thyroid function (Part B and Part C only) ▪ TSH ▪ Free T4 o Urine to test for drugs of abuse (illegal and prescription) o Urine tests to check your albumin/ creatinine ratio o Females who have not had a period for at least 12 months in a row will have a blood hormone test to confirm they cannot have children • The study investigator may decide to do an alcohol breath test • The use of proper birth control will be reviewed (males only) • You will be asked “How do you feel?” HIV, hepatitis B, and hepatitis C will be tested at screening. If anyone is exposed to your blood during the study, you will have these tests done again. If you have a positive test, you cannot be in or remain in the study. HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). If your HIV test is positive, you will be told about the results. It may take weeks or months after being infected with HIV for the test to be positive. The HIV test is not always right. Having certain infections or positive test results may have to be reported to the State Department of Health. This includes results for HIV, hepatitis, and other infections. If you have any questions about what information is required to be reported, please ask the study investigator or study staff. Although this testing is meant to be private, complete privacy cannot be guaranteed. For example, it is possible for a court of law to get health or study records without your permission.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Medication 1. Xxxxxxx’s physician shall prescribe and monitor adequate dosage levels for each Client. 2. Xxxxxxx’s physician shall not impose and/or limit dosage capitations for any prescribed medication for the treatment of opioid use disorder.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!